8-K: BioAffinity Secures $4.8M, Regains Nasdaq Compliance

BioAffinity Technologies successfully closed a $4.8 million public offering and regained compliance with Nasdaq listing requirements, including the minimum bid price and stockholders' equity.

Summary

• Closed a public offering of 1,047,694 shares of common stock and 874,067 pre-funded warrants, generating aggregate gross proceeds of approximately $4.8 million.
• Common stock was sold at $2.50 per share, and pre-funded warrants at $2.493 each, with an exercise price of $0.007 per share.
• Proceeds from the offering are intended for working capital and other general corporate purposes.
• Regained compliance with Nasdaq's Minimum Bid Price Requirement, having maintained a bid price above $1.00 for seven consecutive trading days following a 1-for-30 reverse stock split.
• Believes to have regained compliance with Nasdaq's Continued Listing Equity Requirement, with stockholders' equity in excess of $2,500,000, pending Nasdaq's confirmation.
• The reverse stock split eliminated approximately $4 million in warrant-related derivative liabilities, converting them into stockholders' equity.
• Amendments to May 2025 warrants are expected to reclassify them, increasing stockholders' equity by approximately $2.8 million.
• Received approximately $1.3 million from the exercise of outstanding warrants since June 30, 2025.
• Outstanding shares of Common Stock after the offering and certain warrant exercises total 3,100,402.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the successful capital raise and the company's proactive steps to regain and maintain Nasdaq listing compliance, which were significant challenges. The financial improvements from liability elimination and warrant reclassification also contribute positively. However, the necessity of a reverse stock split and prior non-compliance temper the overall sentiment from being extremely positive.

Positives

• Successfully raised approximately $4.8 million in gross proceeds through a public offering, strengthening the company's financial position.
• Regained compliance with Nasdaq's Minimum Bid Price Requirement, reducing immediate delisting concerns.
• Believes to have regained compliance with Nasdaq's Continued Listing Equity Requirement, addressing another significant listing deficiency.
• Elimination of approximately $4 million in warrant-related derivative liabilities and an expected $2.8 million increase in stockholders' equity from warrant reclassification improve the balance sheet.
• Received $1.3 million from warrant exercises, indicating investor confidence and providing additional capital.

Negatives

• Required a 1-for-30 reverse stock split to meet Nasdaq's Minimum Bid Price Requirement, often perceived negatively by the market.
• Experienced prior non-compliance with multiple Nasdaq listing rules (Minimum Bid Price and Continued Listing Equity Requirement), leading to a delisting threat and appeal process.

Risks

• The ability to close the offering when anticipated, as mentioned in forward-looking statements.
• General risks and uncertainties that could cause actual results to differ materially from current expectations, as discussed in the company's Annual Report on Form 10-K and subsequent SEC filings.
• Potential for market price of publicly-traded securities to be negatively impacted by past or future open market or derivative transactions, including Short Sales, by purchasers.
• The company awaits Nasdaq's confirmation of compliance with the Continued Listing Equity Requirement, and failure to maintain compliance could still lead to delisting.

Future Outlook

The company intends to use the net proceeds from the public offering for working capital and other general corporate purposes. It is actively working to maintain its Nasdaq listing by demonstrating compliance with the Minimum Bid Price and Continued Listing Equity Requirements, with a deadline of October 2, 2025. The placement agent has a right of first refusal for future public and private equity, equity-linked, convertible, or debt offerings until December 30, 2025.

Management Comments

• Maria Zannes, President and Chief Executive Officer, signed the Current Report on Form 8-K.

Industry Context

BioAffinity Technologies operates in the biotechnology sector, focusing on noninvasive tests for early-stage cancer detection and broad-spectrum cancer treatments. Its primary product, CyPath Lung, is a noninvasive test for early-stage lung cancer, marketed as a Laboratory Developed Test (LDT) by its subsidiary, Precision Pathology Laboratory Services. The capital raise and resolution of listing issues are critical for continued research, development, and commercialization efforts in this competitive and capital-intensive industry.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks.

Corporate Governance

Legal Proceedings

• The company was notified by Nasdaq of non-compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)) and the Continued Listing Equity Requirement (Rule 5550(b)(1)).
• The company appealed Nasdaq's delisting decision, which stayed the delisting pending a panel decision.
• Nasdaq granted an extension until October 2, 2025, to demonstrate compliance with both listing requirements.

Stakeholder Impact

• Shareholders benefit from the capital infusion, which supports ongoing operations and strategic initiatives, and the maintained Nasdaq listing, which preserves liquidity and market access.
• Investors in the offering gain exposure to the company's biotechnology focus, particularly CyPath Lung, and participate in the capital raise at a set price.
• Employees and management benefit from the company's continued operations and stability provided by the capital raise and Nasdaq listing.

Next Steps

• Awaiting Nasdaq's confirmation of compliance with the Continued Listing Equity Requirement.
• The company is restricted from issuing certain equity securities for 45 days and variable rate transactions for 6 months following the offering's closing, with exceptions for at-the-market offerings after 45 days.
• The placement agent holds a right of first refusal for future public and private equity, equity-linked, convertible, or debt offerings until December 30, 2025.

Key Dates

Recommendation

The company has successfully addressed critical Nasdaq listing deficiencies through a reverse stock split and a capital raise, which are significant positive developments. The $4.8 million in gross proceeds, coupled with the elimination of derivative liabilities and reclassification of warrants, substantially improves the company's financial health and liquidity. However, the need for a reverse stock split and the prior non-compliance indicate underlying operational and market challenges. While the immediate threats are mitigated, sustained operational improvement, consistent financial performance, and continued market confidence are necessary for long-term growth. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor the company's execution on its strategic initiatives and its ability to maintain Nasdaq compliance and improve its core business.

Keywords

Biotechnology, Public Offering, Pre-Funded Warrants, Nasdaq Compliance, Reverse Stock Split, Capital Raise, Cancer Detection, CyPath Lung, SEC Filing, Financial Reporting